ImmuCell

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ImmuCell (ICCC) reports stellar Q1 sales growth but faces margin challenges and regulatory delays

ImmuCell's Q1 2024 earnings call highlighted strong sales growth, operational achievements, margin challenges, and regulatory hurdles. The company aims to navigate these obstacles to drive future profitability and growth.

ImmuCell reports sales growth but struggles with margins and production

ImmuCell Corporation's Q2 2024 earnings call highlighted strong sales growth, challenges in gross margin improvement, and ongoing efforts to address production issues and regulatory processes. Despite improvements in EBITDA, the company faces financial constraints and operational hurdles that require strategic remediation.

ImmuCell reports robust sales growth and positive EBITDA in Q3

ImmuCell's Q3 2024 performance reflects strong sales growth, improved financial metrics, and a focus on innovation and partnerships.
While facing challenges in production and margin targets, the company is well-positioned to leverage opportunities for growth and profitability.
Overall, ImmuCell's strategic initiatives and financial progress signal a positive trajectory amidst operational challenges and regulatory processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2022 Earnings Conference Call May 13, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Joseph Crabb - Former Chief Scientific Officer and VP Operator Good morning. This is Andrea from Chorus Call.

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2022 Results - Earnings Call Transcript

Q1 2022 Product Sales Increased 46% over Q1 2021 Q1 2022 Product Sales Increased 46% over Q1 2021

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022

Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022

PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs.

UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Mark Wustenberg, DVM has joined its sales and marketing team as Commercial Leader of Stakeholder Engagement.

Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

PORTLAND, Maine, April 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter ended March 31, 2022.

ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022

ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript

Annual Product Sales for 2021 Increased 25% over 2020 Annual Product Sales for 2021 Increased 25% over 2020

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

PORTLAND, Maine, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2021.

ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021

ImmuCell Corp (ICCC) CEO Michael Brigham on Q3 2021 Results - Earnings Call Transcript

Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000) Q3 2021 Net Income of $148,000 versus Q3 2020 Net Loss of ($323,000)

ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021

Conference Call Scheduled for Tuesday, November 16, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 16, 2021 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Third Quarter Ended September 30, 2021

PORTLAND, Maine, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter ended September 30, 2021.

ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021

PORTLAND, Maine, Sept. 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the expansion of its commercial team with the hiring of Dr. Raffael Lichdi as Commercial Research & Technical Services Veterinarian.

Raffael Lichdi, DVM Joins ImmuCell's Sales & Marketing Team

New York, New York--(Newsfile Corp. - September 2, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ImmuCell Corporation ("ImmuCell" or the "Company") (NASDAQ: ICCC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether ImmuCell and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmuCell Corporation - ICCC

PORTLAND, Maine, Aug. 24, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that the FDA has issued a Technical Section Incomplete Letter covering the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain ® (Nisin A intramammary solution).

ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain®

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2021 Results - Earnings Call Transcript

Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000)

ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021

Conference Call Scheduled for Friday, August 13, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, August 13, 2021 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021

PORTLAND, Maine, July 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter ended June 30, 2021.

ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2021 Results - Earnings Call Transcript

PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2021.

ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021

Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021

PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment.

News for ImmuCell Stock (ICCC)